Health Care Cost and Utilization Associated With Alpha-1 Antitrypsin Deficiency Among A Cohort of Medicare Beneficiaries With Copd.

test, Wilcoxon test, Chi-square test) were: number of patients exposed to allogeneic red cells, amount of blood transfusions, and the number of length of stay in hospital. An economic model was quantified the cost saving of EVICEL® in ICH. Results: preliminary results showed that application of EVICEL reduce number of transfused RBC, postoperative haemoglobin loss, and days of hospital stay. In the hospital cost. analysis EVICEL® predicts resource reduction with average cost-savings of € 1.227 per patient. ConClusions: Overall, the results suggest that EVICEL are efficacious in reducing both post-operative blood loss, and hospital stay The protocol with EVICEL® produce clinical appropriateness and important cost savings for hospital.